ERAS
Price
$1.40
Change
-$0.02 (-1.41%)
Updated
Apr 24, 04:53 PM (EDT)
Capitalization
390.91M
14 days until earnings call
LENZ
Price
$27.23
Change
+$0.28 (+1.04%)
Updated
Apr 24, 02:36 PM (EDT)
Capitalization
710.34M
Ad is loading...

ERAS vs LENZ

Header iconERAS vs LENZ Comparison
Open Charts ERAS vs LENZBanner chart's image
Erasca
Price$1.40
Change-$0.02 (-1.41%)
Volume$767
Capitalization390.91M
LENZ Therapeutics
Price$27.23
Change+$0.28 (+1.04%)
Volume$300
Capitalization710.34M
ERAS vs LENZ Comparison Chart
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LENZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. LENZ commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and LENZ is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (ERAS: $1.42 vs. LENZ: $27.01)
Brand notoriety: ERAS and LENZ are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 125% vs. LENZ: 102%
Market capitalization -- ERAS: $390.91M vs. LENZ: $710.34M
ERAS [@Biotechnology] is valued at $390.91M. LENZ’s [@Biotechnology] market capitalization is $710.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileLENZ’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • LENZ’s FA Score: 0 green, 5 red.
According to our system of comparison, LENZ is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while LENZ’s TA Score has 7 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 3 bearish.
  • LENZ’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, LENZ is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а +21.37% price change this week, while LENZ (@Biotechnology) price change was +17.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.72%. For the same industry, the average monthly price growth was -5.54%, and the average quarterly price growth was -12.32%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

LENZ is expected to report earnings on Mar 19, 2025.

Industries' Descriptions

@Biotechnology (+7.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LENZ($710M) has a higher market cap than ERAS($391M). LENZ YTD gains are higher at: -6.443 vs. ERAS (-43.426). ERAS has more cash in the bank: 319M vs. LENZ (217M). LENZ has less debt than ERAS: LENZ (1.58M) vs ERAS (52.9M).
ERASLENZERAS / LENZ
Capitalization391M710M55%
EBITDA-151.33MN/A-
Gain YTD-43.426-6.443674%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash319M217M147%
Total Debt52.9M1.58M3,352%
TECHNICAL ANALYSIS
Technical Analysis
ERASLENZ
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 8 days ago
88%
Bearish Trend 17 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LENZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GABSX38.53N/A
N/A
Gabelli Small Cap Growth AAA
JATIX54.29N/A
N/A
Janus Henderson Glb Tech and Innovt I
EAPDX14.91N/A
N/A
Parametric Dividend Income A
KTRZX8.39N/A
N/A
DWS Global Income Builder R6
BLYCX24.63N/A
N/A
American Beacon Man Lg Cp Growth C

LENZ and

Correlation & Price change

A.I.dvisor indicates that over the last year, LENZ has been loosely correlated with KYMR. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LENZ jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LENZ
1D Price
Change %
LENZ100%
+4.73%
KYMR - LENZ
46%
Loosely correlated
+6.56%
ACLX - LENZ
43%
Loosely correlated
+0.81%
ELVN - LENZ
43%
Loosely correlated
-1.45%
ATXS - LENZ
42%
Loosely correlated
+12.55%
ERAS - LENZ
42%
Loosely correlated
+2.90%
More